<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617577</url>
  </required_header>
  <id_info>
    <org_study_id>ADDF-GCSF</org_study_id>
    <nct_id>NCT01617577</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Filgrastim in Alzheimer's Disease</brief_title>
  <acronym>FFAD</acronym>
  <official_title>Efficacy and Safety of Filgrastim as a Pro‐Cognitive Agent in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Filgrastim (G-CSF) is widely used for treatment of patients who have a deficiency of white
      blood cells. It is also routinely used to stimulate and mobilize stem/progenitor cells for
      bone marrow transplantation. In studies of thousands of healthy donor subjects treated with
      G-CSF, the side-effects profile has been reported to be mild and reversible. Currently, G-CSF
      is under investigation in clinical trials in Germany and the US that aim to enhance recovery
      from strokes and heart attacks. In animal studies, G-CSF has been observed to improve
      cognitive performance and to markedly reduce amyloid deposition in hippocampus and entorhinal
      cortex in a mouse model of Alzheimer's Disease (AD). Since this drug is being used safely in
      many people throughout the world, the investigators hypothesize that it will also be safe to
      give to patients with Alzheimer's disease and that it may improve some aspects of memory and
      thinking. The present pilot study has two goals or objectives: 1) to investigate the effects
      of a five day schedule of Filgrastim administration on cognitive function and 2) to assess
      its tolerability and safety in a small group (12 patients) with mild to moderate stage AD.
      Patients who are eligible for the study will be randomly assigned to one of two groups (n=6
      per group). One group will receive a five-day course of Filgrastim injections and the other
      group of subjects will receive vehicle injections (solution without drug). At the end of the
      first phase of the study (week 8), the groups will cross over to receive either vehicle or
      Filgrastim as appropriate. In this way all subjects will have received the active medication
      by the end of the study. After the study is finished the investigators should know whether or
      not Filgrastim improves some aspects of thinking and memory. And the investigators should
      know whether or not it is safe to give this medication to patients with Alzheimer's disease.
      To ensure that the drug is safe, a Safety Monitoring Committee will oversee the entire study.
      They will review all laboratory data, including complete blood counts, serum chemistry, EKGs
      and adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was originally designed to have two arms (GCSF first followed by placebo= Arm 1;
      placebo followed by GCSF=Arm2). Total length of study for each subject was 14 weeks, with
      crossover on week 7.

      Linear regression models could not be used because of the small number of subjects; n = 5 in
      the first Arm who received G-CSF before crossover to the placebo phase and n = 3 in Arm 2
      (who received placebo first before crossover to the G-CSF treatment phase). The general rule
      for the sample size required for regression analysis is n = 15 per covariate. Therefore,
      comparison of the final cognitive scores on visit 5 (week 14) were compared to scores at
      baseline (visit 1) for all subjects (n = 8) using the Wilcoxon signed rank test. Plasma
      cytokine changes were plotted to compare effects following G-CSF to that following placebo,
      regardless of the order of treatment. Wilcoxon sum rank test was used to test differences
      between G-CSF treatment and placebo treatment at specific intervals after treatment.
      Statistical Package for the Social Sciences (SPSS Version 19) was used for all data analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )</measure>
    <time_frame>Baseline and 2wk and 4 wk after Rx;</time_frame>
    <description>Scores from each of the cognitive assessments:
mean ADAScog: a decrease in total score units = improvement, min=0 max=31 mean PAL (memory): an increase in score = improvement, min= 0 max=12 mean PAL (total trial adj): a decrease in score = improvement,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )</measure>
    <time_frame>Baseline and final visit (14 wks)</time_frame>
    <description>Scores from each of the cognitive assessments:
mean ADAScog: a decrease in total score units = improvement, min=0 max= mean PAL (memory): an increase in score = improvement, mean PAL (total trial adj): a decrease in score = improvement,</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>G-CSF (filgrastim) first phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first phase</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF; filgrastim</intervention_name>
    <description>The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days</description>
    <arm_group_label>G-CSF (filgrastim) first phase</arm_group_label>
    <other_name>Neupogen; granulocyte colony stimulating factor (GCSF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days</description>
    <arm_group_label>Placebo first phase</arm_group_label>
    <other_name>Vehicle (5% dextrose water or D5W)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  People with probable AD (by NINDS/ADRDA criteria) who are likely to be testable at the
             conclusion of the study period, and who do not have concurrent medical conditions or
             medications that might influence cognitive testing or that would increase the risk of
             treatment

          -  The participants will have a Min Mental State Examination score of between 10 and 24

          -  stable medical condition and stable medications for 3 months prior to screening

          -  study partner (spouse or caregiver) to accompany patient to all scheduled visits; able
             to complete baseline assessments

          -  physically acceptable for this study as confirmed by medical history, physical exam,
             neurological exam and clinical tests

        Exclusion Criteria:

          -  clinically significant cardiac arrhythmia

          -  history of clinically significant stroke

          -  use of another investigational drug within 2 months of screening

          -  current evidence or history in the past 2 years of epilepsy, focal brain lesion, head
             injury with loss of consciousness or DSM‐IV criteria for any major psychiatric
             disorder including psychosis, major depression, bipolar disorder alcohol or substance
             abuse; residence in a skilled nursing facility (but patients in assisted living
             facility are acceptable)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USF/Byrd Alzheimer's Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alzdiscovery.org/</url>
  </link>
  <reference>
    <citation>Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, Mori T, Cao C, Arendash GW. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience. 2009 Sep 29;163(1):55-72. doi: 10.1016/j.neuroscience.2009.05.071. Epub 2009 Jun 14.</citation>
    <PMID>19500657</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <results_first_submitted>June 29, 2012</results_first_submitted>
  <results_first_submitted_qc>November 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 27, 2012</results_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>G-CSF</keyword>
  <keyword>granulocyte colony stimulating factor</keyword>
  <keyword>Filgrastim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>G-CSF First Phase</title>
          <description>Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days</description>
        </group>
        <group group_id="P2">
          <title>Placebo First Phase</title>
          <description>Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>G-CSF First Phase</title>
          <description>Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days</description>
        </group>
        <group group_id="B2">
          <title>Placebo First Phase</title>
          <description>Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.6" spread="3.8"/>
                    <measurement group_id="B2" value="75.2" spread="3.1"/>
                    <measurement group_id="B3" value="72.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )</title>
        <description>Scores from each of the cognitive assessments:
mean ADAScog: a decrease in total score units = improvement, min=0 max=31 mean PAL (memory): an increase in score = improvement, min= 0 max=12 mean PAL (total trial adj): a decrease in score = improvement,</description>
        <time_frame>Baseline and 2wk and 4 wk after Rx;</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF</title>
            <description>All participants received G-CSF either in the first or second phase of the crossover</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants received placebo either in the first or second phase of crossover</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )</title>
          <description>Scores from each of the cognitive assessments:
mean ADAScog: a decrease in total score units = improvement, min=0 max=31 mean PAL (memory): an increase in score = improvement, min= 0 max=12 mean PAL (total trial adj): a decrease in score = improvement,</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADAScog Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.25" spread="2.49"/>
                    <measurement group_id="O2" value="22.25" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADAScog 2wk post Rx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="1.67"/>
                    <measurement group_id="O2" value="17.75" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADAScog 4wks post Rx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="2.507"/>
                    <measurement group_id="O2" value="20.125" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PALmem baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="0.59"/>
                    <measurement group_id="O2" value="2.75" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PALmem 2wk post Rx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="0.857"/>
                    <measurement group_id="O2" value="3.75" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PALmem 4wk post RX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="1.477"/>
                    <measurement group_id="O2" value="4.75" spread="0.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAL (tot trial adj) baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.87" spread="3.02"/>
                    <measurement group_id="O2" value="33.87" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAL (tot trial adj) 2wk post Rx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.48" spread="6.16"/>
                    <measurement group_id="O2" value="33.62" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAL(tot trial adj) 4wk post RX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.45" spread="5.36"/>
                    <measurement group_id="O2" value="30.62" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )</title>
        <description>Scores from each of the cognitive assessments:
mean ADAScog: a decrease in total score units = improvement, min=0 max= mean PAL (memory): an increase in score = improvement, mean PAL (total trial adj): a decrease in score = improvement,</description>
        <time_frame>Baseline and final visit (14 wks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Placebo</title>
            <description>All participants received G-CSF and placebo in crossover order</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )</title>
          <description>Scores from each of the cognitive assessments:
mean ADAScog: a decrease in total score units = improvement, min=0 max= mean PAL (memory): an increase in score = improvement, mean PAL (total trial adj): a decrease in score = improvement,</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADAScog Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADAScog 14wks post Rx</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.37" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PALmem baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PALmem 14wk post RX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAL (tot trials adj) baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.88" spread="3.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAL (tot trials adj) 14wk post RX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30." spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ADAScog scores at baseline vs final visit (wk 14); null hypothesis is there is no difference between scores</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>PAL(mem) at baseline and 14 wk (final visit): null hypothesis is thereis no difference in score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>PALtot trials adj at baseline vs 14wk (final visit)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>subjects who received placebo in either phase of the study</description>
        </group>
        <group group_id="E2">
          <title>G-CSF</title>
          <description>participants who received GCSF injecitons during first or second phase</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>generalized aches</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>relieved in all subjects with non-steroidal anti-inflammatory agents (tyelone or motrin)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>all headaches occured after lumbar puncture regardless of GCSF or placebo treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>visual hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Juan Sanchez-Ramos</name_or_title>
      <organization>University of South Florida</organization>
      <phone>813-974-5841</phone>
      <email>jsramos@health.usf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

